NeuroPace (NASDAQ:NPCE) Downgraded by Leerink Partners to Market Perform

Leerink Partners cut shares of NeuroPace (NASDAQ:NPCE) from an outperform rating to a market perform rating in a research report released on Friday morning, Marketbeat.com reports. The firm currently has $7.00 target price on the stock.

Several other equities analysts have also issued reports on NPCE. Weiss Ratings lowered NeuroPace from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Friday, October 2nd. Cantor Fitzgerald reiterated an “overweight” rating on shares of NeuroPace in a research report on Tuesday, September 15th. Guggenheim reissued a “neutral” rating on shares of NeuroPace in a research note on Wednesday, July 29th. Mizuho started coverage on shares of NeuroPace in a report on Thursday, July 23rd. They issued an “outperform” rating and a $22.00 target price on the stock. Finally, JPMorgan Chase & Co. cut shares of NeuroPace from an “overweight” rating to a “neutral” rating and cut their target price for the stock from $20.00 to $9.00 in a report on Friday. Five investment analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, NeuroPace presently has an average rating of “Hold” and an average price target of $15.50.

NeuroPace Trading Down 37.1%

NASDAQ NPCE opened at $7.56 on Friday. The company has a current ratio of 4.94, a quick ratio of 3.91 and a debt-to-equity ratio of 4.97. The business has a fifty day simple moving average of $13.21 and a 200 day simple moving average of $14.75. NeuroPace has a 12 month low of $5.46 and a 12 month high of $19.60. The firm has a market capitalization of $259.46 million, a P/E ratio of -13.50 and a beta of 1.98.

NeuroPace (NASDAQ:NPCE) last announced its quarterly earnings data on Tuesday, August 11th. The company reported ($0.18) earnings per share for the quarter, topping the consensus estimate of ($0.22) by $0.04. NeuroPace had a negative return on equity of 110.26% and a negative net margin of 20.00%. The company had revenue of $22.83 million during the quarter, compared to analyst estimates of $22.61 million. On average, analysts predict that NeuroPace will post -0.67 EPS for the current fiscal year.

Institutional Trading of NeuroPace

A number of large investors have recently made changes to their positions in the business. BlackRock Inc. purchased a new position in NeuroPace during the 2nd quarter worth $39,369,000. GSA Capital Partners LLP purchased a new stake in NeuroPace in the second quarter valued at about $1,836,000. First Light Asset Management LLC raised its stake in NeuroPace by 16.3% in the second quarter. First Light Asset Management LLC now owns 2,861,167 shares of the company’s stock valued at $45,464,000 after buying an additional 401,201 shares during the last quarter. Deutsche Bank AG purchased a new stake in NeuroPace in the second quarter valued at about $14,919,000. Finally, Man Group plc acquired a new stake in NeuroPace in the second quarter worth about $1,336,000. 78.83% of the stock is currently owned by institutional investors.

Latest NeuroPace News

Here’s some of the latest news about NPCE:

• Negative Sentiment: Q3 revenue was $23.1 million, below the cited $27.1 million analyst estimate. Revenue from the company’s RNS System grew just 1.4% year over year, signaling limited near-term growth. NeuroPace Q3 results and guidance
• Negative Sentiment: The company cut its 2026 revenue outlook to $91–$92 million, well below the roughly $100.4 million consensus estimate, reinforcing concerns about its sales trajectory. Revenue miss and lowered outlook
• Negative Sentiment: Analyst actions added pressure: JPMorgan cut its rating to neutral and lowered its target from $20 to $9; Wells Fargo and Leerink Partners also downgraded the shares. KeyCorp maintained an overweight rating but cut its target from $18 to $14. Analyst rating changes

About NeuroPace

NeuroPace, Inc. is a medical technology company focused on treating people with drug-resistant epilepsy. Its primary product is the RNS System, an implanted responsive neurostimulation device designed to detect patterns of abnormal electrical activity in the brain and deliver stimulation in response. The RNS System includes a neurostimulator implanted in the skull and leads placed in or near seizure-onset areas of the brain. Clinicians use the system to review brain activity and adjust treatment, while patients can use accompanying tools to record information about their seizures and share it with their care team.